Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
211At-labeled anti-CD3 antibody
- Development stage
- Preclinical
- Lead developer
- Fred Hutchinson Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
211At-labeled anti-CD3 antibody is an alpha-emitting radioimmunotherapy candidate designed for rapid, targeted, and non-genotoxic T-cell depletion. It consists of an anti-CD3 monoclonal antibody (specifically clone SP34-R1) conjugated to the alpha-particle emitting radioisotope astatine-211 (211At) via a boron cage pendant group (B10). The mechanism of action involves the delivery of high-energy, short-range alpha radiation directly to CD3-expressing T-cells, causing potent cell death while minimizing off-target toxicity and avoiding the genotoxicity associated with conventional chemotherapy-based lymphodepletion. Developed by researchers at the University of Washington and Fred Hutchinson Cancer Center, this agent is being evaluated for applications in CAR T-cell therapy conditioning, HIV cure strategies, and the treatment of T-cell-mediated conditions such as autoimmune diseases and T-cell malignancies.
- Other names
- 211At-anti-CD3 antibodyastatine-211-labeled anti-CD3 antibodyastatine211-labeled anti-CD3 antibodyastatine 211-labeled anti-CD3 antibody
02
Targets
CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on 211At-labeled anti-CD3 antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 211At-labeled anti-CD3 antibody.